[CTLA4-Ig (abatacept)].

Although tumor necrosis factor (TNF) antagonists have dramatically improved the outcome of patients with rheumatoid arthritis (RA), some of the patients do not respond or cannot tolerate these drugs. Abatacept is a recombinant fusion protein containing components of IgG and cytotoxic T-lymphocyte-associated antigen-4 that inhibit costimulatory signal from antigen presenting cells and prevent activation of T cells. Several clinical trials have demonstrated the excellent efficacy and safety of abatacept in patients with RA who are resistant to methotrexate or TNF antagonists. Abatacept improved clinical signs and symptoms and quality of life of patients with RA and also retarded their radiological progression of structural damage of affected joints. The safety concerns, especially for infections and malignancies, are raised and should be strictly monitored in clinical trials and future clinical practice in Japan as well as in Western countries.
AuthorsMasayoshi Harigai
JournalNihon rinsho. Japanese journal of clinical medicine (Nihon Rinsho) Vol. 65 Issue 7 Pg. 1231-7 (Jul 2007) ISSN: 0047-1852 [Print] Japan
PMID17642237 (Publication Type: English Abstract, Journal Article, Review)
Chemical References
  • Antirheumatic Agents
  • Immunoconjugates
  • Abatacept
  • Abatacept
  • Antigen-Presenting Cells (immunology)
  • Antirheumatic Agents (adverse effects, chemistry, pharmacology, therapeutic use)
  • Arthritis, Rheumatoid (drug therapy, immunology)
  • Clinical Trials as Topic
  • Drug-Related Side Effects and Adverse Reactions
  • Humans
  • Immunoconjugates (adverse effects, chemistry, pharmacology, therapeutic use)
  • Lymphocyte Activation
  • T-Lymphocytes (immunology)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password:
Type Validation Code Shown: